March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
Learn why healthy bones are important, what puts you at risk for bone loss, and things you can do to prevent or treat bone loss.
Learn about the groundbreaking GRACE study of HIV+ women and how it successfully enrolled large numbers of women of color in a clinical trial.